TITLE

Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects

AUTHOR(S)
Johansen, Odd Erik; Brustad, Ellen; Enger, Steve; Tveit, Arnljot
PUB. DATE
January 2008
SOURCE
Cardiovascular Diabetology;2008, Vol. 7, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Background: The prevalence of atrial fibrillation (AF) is increasing world wide and amongst factors that aggravate the risk is diabetes mellitus (DM), also in epidemic development. However, although DM is a potentially modifiable risk factor for AF, few, if any, studies have explored the prevalence of undiagnosed dysglycaemia among subjects with AF or if duration of AF are related to parameters of glycaemia or dysglycaemia prevalence. Methods: In this case control study, amongst 75-year old subjects with and without AF, the prevalence of dysglycaemia, i.e., impaired fasting glycaemia, impaired glucose tolerance or DM, according to World Health Organisation criteria was assessed by a 75-g oral glucose tolerance test (OGTT). Results: Prevalence of undiagnosed DM among the 108 subjects (male/female 73/35, BMI 25.4 � 3.2) without and the 46 (male/female 34/12, BMI 25.3 � 3.7) with AF (median AF duration five years) where 3.7% and 13.0%, respectively (p = 0.031, Odds ratio (OR) 3.86 (95% Confidence interval [CI]: 1.01, 16.25)) whereas the overall prevalence of dysglycaemia (prediabetes and DM) where similar (respectively 43.5% and 39.1%, p = 0.46, OR 0.83 [95% CI: 0.41, 1.69]). Patients with AF duration = 5 years had however a higher dysglycaemia prevalence (61.1% [DM 22.2%, prediabetes 38.9%]) as compared to AF duration < 5 years (25% [DM 7.1%, prediabetes 17.9%], p = 0.0014, OR 4.7 [95% CI: 1.30, 16.90]) or no AF (p = 0.17, OR 2.04 [95% CI: 0.73, 5.66]). There was also a significant correlation between the duration of AF and HbA1c (r = 0.408, p = 0.005) and fasting glucose levels (r = 0.353, p = 0.016). Conclusion: AF is associated with chronic hyperglycaemia amongst 75-year old subjects. Prediabetes and DM should be pro-actively assessed if AF duration = 5 years.
ACCESSION #
55716387

 

Related Articles

  • Effects of lifestyle education program for type 2 diabetes patients in clinics: study design of a cluster randomized trial. Adachi, Misa; Yamaoka, Kazue; Watanabe, Mariko; Nishikawa, Masako; Hida, Eisuke; Kobayashi, Itsuro; Tango, Toshiro // BMC Public Health;2010, Vol. 10 Issue 1, p742 

    Background: The number of patients with type 2 diabetes is drastically increasing worldwide. It is a serious health problem in Japan as well. Lifestyle interventions can reduce progression from impaired glucose tolerance to type 2 diabetes, and glycemic control has been shown to improve...

  • Estudio Parto: postpartum diabetes prevention program for hispanic women with abnormal glucose tolerance in pregnancy: a randomised controlled trial - study protocol. Chasan-Taber, Lisa; Marcus, Bess H.; Rosal, Milagros C.; Tucker, Katherine L.; Hartman, Sheri J.; Pekow, Penelope; Braun, Barry; Moore Simas, Tiffany A.; Solomon, Caren G.; Manson, JoAnn E.; Markenson, Glenn // BMC Pregnancy & Childbirth;2014, Vol. 14 Issue 1, p1 

    Background: Diabetes and obesity have reached epidemic proportions in the U.S. with rates consistently higher among Hispanics as compared to non-Hispanic whites. Among Hispanic women diagnosed with gestational diabetes mellitus (GDM), 50% will go on to develop type 2 diabetes within 5 years of...

  • Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Yan Shu; Sheardown, Steven A.; Brown, Chaline; Owen, Ryan P.; Shuzhong Zhang; Castro, Richard A.; Ianculescu, Alexandra G.; Lin Yue; Lo, Joan C.; Burchard, Esteban G.; Brett, Claire M.; Giacomini, Kathleen M. // Journal of Clinical Investigation;May2007, Vol. 117 Issue 5, p1422 

    Metformin is among the most widely prescribed drugs for the treatment of type 2 diabetes. Organic cation transporter 1 (OCT1) plays a role in the hepatic uptake of metformin, but its role in the therapeutic effects of the drug, which involve activation of AMP-activated protein kinase (AMPK), is...

  • Research & Markets: Glucose Intolerance Global Clinical Trials Review Q1 2011.  // Biomedical Market Newsletter;3/31/2011, p703 

    The article presents the "Glucose Intolerance Global Clinical Trials Review, Q1 2011" report which provides data on the global glucose intolerance clinical trials including trials by phase, trial status, and prominence of the sponsors.

  • Demand up for better glucose self-monitoring devices.  // Healthcare Purchasing News;May2003, Vol. 27 Issue 5, p24 

    Reports on an increase in the demand for glucose self-monitoring devices in the U.S. Factors that contribute to the growing incidence of diabetes; Reason behind the adoption of devices; Revenue posted by self-monitoring devices market in 2002.

  • Ten-year follow-up report on Birmingham Diabetes Survey of 1961.  // British Medical Journal;7/3/1976, Vol. 2 Issue 6026, p35 

    Focuses on the effects of glucose tolerance test (GTT) on diabetic patients included in the Birmingham Diabetes Survey of 1961 in England. Reactions of patients belonging to the controlled group; Identification of abnormalities of the GTT diabetes; Diagnosis for development of florid diabetes.

  • oral glucose tolerance test.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1639 

    A definition of the term "oral glucose tolerance test," which refers to a screening test for diabetes mellitus, is presented.

  • Fasting Glucose and Progression of Impaired Glucose Tolerance. Cockram, Clive S.; Chou, Pesus; Chia-Lin Li; Shih-Tzer Tsai // Diabetes Care;Feb99, Vol. 22 Issue 2, p369 

    Comments on a study which examined progression of diabetes from impaired glucose tolerance conducted by researcher Pesus Chou. Methodology; Findings of the study; Response from the author of the study.

  • Pioglitazone for diabetes prevention. Elliott, William T. // Infectious Disease Alert;May2011 Clinical Bri, p1 

    The article reports on the discovery that pioglitazone reduces the risk of diabetes among patients with impaired glucose tolerance in an industry-sponsored study.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics